Fenofibrate restores glutamatergic and dopaminergic homeostasis in the nucleus accumbens and reduces alcohol relapse in rats

Isla, Eduardo; Gutierrez-Vega, Ignacio; Quilaqueo, Maria Elena; Herrera-Marschitz, Mario; Quintanilla, Maria Elena; Morales, Paola; Perez-Reytor, Diliana; Rivera-Meza, Mario; Karahanian, Eduardo

Abstract

Alcohol use disorder (AUD) is associated with dysregulation of glutamatergic and dopaminergic signaling within the nucleus accumbens (NAc), contributing to withdrawal syndrome, craving, and relapse. Fenofibrate, an agonist of the peroxisome proliferator-activated receptor alpha (PPAR alpha), reduces alcohol intake; however, its effects on NAc neurotransmission and the relative contributions of central versus peripheral mechanisms remain unclear. Here, we investigated whether fenofibrate administration initiated during alcohol withdrawal and continued throughout reaccess reduces relapse drinking, and whether this effect involves normalization of glutamate and dopamine in the NAc. Fenofibrate treatment during withdrawal produced a sustained reduction in alcohol consumption throughout a 14-day relapse period in high-drinker female rats. This effect was abolished by systemic co-administration of the PPAR alpha antagonist GW6471. Fenofibrate increased hepatic catalase activity and upregulated the glutamate transporter GLT-1 in the NAc, while dopamine transporter (DAT) protein levels remained unchanged. When GW6471 was administered intracerebroventricularly to block central PPAR alpha activation selectively, the reduction in alcohol intake was only partially attenuated, indicating that approximately one-third of fenofibrate's effect is centrally mediated, whereas two-thirds result from peripheral mechanisms. No-net-flux microdialysis showed that fenofibrate enhanced uptake rates for both glutamate and dopamine in the NAc. Steady-state extracellular glutamate levels were unchanged, whereas extracellular dopamine levels were significantly reduced, consistent with increased functional DAT activity. These findings demonstrate that fenofibrate reduces relapse-like alcohol consumption through a combination of peripheral and CNS PPAR alpha-dependent mechanisms, restoring key aspects of glutamatergic and dopaminergic homeostasis in the NAc, highlighting PPAR alpha activation as a promising therapeutic strategy for AUD.

Más información

Título según WOS: ID WOS:001732636100001 Not found in local WOS DB
Título de la Revista: FRONTIERS IN PHARMACOLOGY
Volumen: 17
Editorial: FRONTIERS MEDIA SA
Fecha de publicación: 2026
DOI:

10.3389/fphar.2026.1792426

Notas: ISI